Identification | Back Directory | [Name]
U-63557A | [CAS]
85666-17-7 | [Synonyms]
U-63557A FUREGRELATE SODIUM SODIUM FUREGRELATE furegralate sodium FUREGRELATE SODIUM SALT Furegrelate Sodium (U-63557A) Sodium 5-(3-pyridinylmethyl)-2-benzofurancarboxylate 5-(3'-Pyridinylmethyl)benzofuran-2-carboxylate sodium sodium:5-(pyridin-3-ylmethyl)-1-benzofuran-2-carboxylate 5-(3-Pyridylmethyl)benzofuran-2-carboxylic acid sodium salt 5-[3,PYRIDINYLMETHYL]BENZO-FURAN-CARBOXYLIC ACID SODIUM SALT 5-(3-PYRIDINYLMETHYL)-2-BENZOFURANCARBOXYLIC ACID, SODIUM SALT 2-Benzofurancarboxylic acid, 5-(3-pyridinylmethyl)-, sodium salt 5-(3-Pyridinylmethyl)benzofurancarboxylic acid sodium-potassium salt | [Molecular Formula]
C15H10NNaO3 | [MDL Number]
MFCD00058448 | [MOL File]
85666-17-7.mol | [Molecular Weight]
275.23 |
Chemical Properties | Back Directory | [storage temp. ]
−20°C | [solubility ]
DMF: >25 mg/ml; DMSO: >21 mg/ml; Ethanol: >14.5 mg/ml; PBS pH 7.2: >16.5 mg/ml | [form ]
White to off-white crystalline solid. | [color ]
White to light yellow | [Water Solubility ]
Soluble in water at approximately 15mg/ml |
Hazard Information | Back Directory | [Uses]
Inhibitor (thromboxane synthetase). | [in vivo]
Furegrelate Sodium (1-5 mg/kg; po) prevents blockage of the coronary artery[1].
Furegrelate Sodium (0.1-5 mg/kg; i.v.) prevents the blockage of stenosed coronary arteries caused platelet aggregation[1].
Furegrelate Sodium blunts the development of hypoxia-induced pulmonary arterial hypertension (PAH) in an established neonatal piglet model primarily by preserving the structural integrity of the pulmonary vasculature[2].
Furegrelate has a long half-life compared to several other drugs used to treat PAH, including nitric oxide and prostagcyclin analogues; And Furegrelate is highly specific to the target enzyme[2]. Animal Model: | Mongrel dogs (19-30 kg)[1] | Dosage: | 1-5 mg/kg | Administration: | Oral (via a gastric tube) | Result: | Prevented blockage of the coronary artery. |
|
|
Company Name: |
BOC Sciences
|
Tel: |
16314854226 |
Website: |
www.bocsci.com |
|